Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire drops Dynepo but raises revenue guidance

This article was originally published in Scrip

Executive Summary

Shireis to drop its anaemia treatment Dynepo (epoetin delta) after the drug performed poorly in the second quarter, earning just $7 million. Dynepo was launched in Europe in March last year but has continued to disappoint, making just $14 million last year and another $14 million in the first half of this year. Shire attributed the discontinuation to significant reductions in prices following the entry of bio-similars to the market. The company recorded charges of $150 million as a result of the move, but said that it would redirect its resources to the launches of products such as Mezavant (mesalazine) and Daytrana (methylphenidate transdermal system) in Europe.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC003304

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel